Co-Diagnostics, Inc. to Present at the Fourth Annual Robins Equity Research Roundup
20 September 2018 - 8:30PM
Business Wire
Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular
diagnostics company with a unique, proprietary platform for the
development of molecular diagnostic tests, announced today that it
will be presenting at the Fourth Annual Robins Equity Research
Roundup, held September 25 – 26, 2018 near Portland, Oregon.
The Equity Research Roundup is sponsored by Catalyst Research
Management Group, RIA, to offer opportunities for portfolio, hedge,
and mutual fund managers, individual investors, and retail brokers
to become acquainted with up-and-coming public and private
companies. In addition to company presentations from a range of
industries, the conference will also facilitate company
introductions to influential members of the investment community.
Co-Diagnostics CEO Dwight Egan will be presenting at 10:30 AM PDT
on September 25th.
Mr. Egan remarked: “We are excited to return to the Equity
Research Roundup and to share the progress we have made since our
presentation a year ago. We believe that Marc Robins’ experience
advocating for public micro-cap companies and experience in
bringing them together with notable members of the investment world
will facilitate telling our story to that community.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets a new,
state-of-the-art diagnostics technology. The Company’s technology
is utilized for tests that are designed using the detection and/or
analysis of nucleic acid molecules (DNA or RNA). The Company also
uses its proprietary technology to design specific tests to locate
genetic markers for use in industries other than infectious disease
and license the use of those tests to specific customers.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking
statements in this release include statements regarding the (i) use
of funding proceeds, (ii) expansion of product distribution, (iii)
acceleration of initiatives in liquid biopsy and SNP detection,
(iv) use of the Company’s liquid biopsy tests by laboratories, (v)
capital resources and runway needed to advance the Company’s
products and markets, (vi) increased sales in the near-term, (vii)
flexibility in managing the Company’s balance sheet, (viii)
anticipation of business expansion, and (ix) benefits in research
and worldwide accessibility of the CoPrimer technology and its
cost-saving and scientific advantages. Forward-looking statements
are subject to inherent uncertainties, risks and changes in
circumstances. Actual results may differ materially from
those contemplated or anticipated by such forward-looking
statements. Readers of this press release are cautioned not to
place undue reliance on any forward-looking statements. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180920005262/en/
Company Contact:Co-Diagnostics Investor RelationsAndrew
Benson, 801-438-1036investors@codiagnostics.comorInvestor
Contact:Lytham Partners, LLCJoe Diaz, Robert Blum and Joe
Dorame602-889-9700
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2024 to May 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From May 2023 to May 2024